TCM
IDXX icon

Triumph Capital Management’s Idexx Laboratories IDXX Stock Holding History

Triumph Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.48K Sell
18
-2
-10% -$1.12K ﹤0.01% 1168
2026
Q1 		$11.2K Buy
20
+10
+100% +$6.41K ﹤0.01% 1085
2025
Q4 		$6.76K Buy
+10
New +$6.81K ﹤0.01% 1179

Other funds holding IDXX

MBI
Montrusco Bolton Investments Montreal, Quebec, Canada $6.46B AUM 26.7% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
SIM
Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return
MJRIC
Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
MIM
Manitou Investment Management Toronto, Ontario, Canada $538M AUM 13.79% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Triumph Capital Management's IDXX Position: Q2 2026 in Review

Triumph Capital Management reduced its Idexx Laboratories (IDXX) stake by 10% in Q2 2026, selling an estimated $1.12K and leaving 18 shares worth $9.48K. The position accounts for ﹤0.01% of the portfolio, ranked #1168.

Triumph Capital Management first reported a position in IDXX in Q4 2025 and has held it in 3 quarters since. The position peaked at $11.2K in Q1 2026. 289 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Triumph Capital Management held 18 shares of Idexx Laboratories worth $9.48K as of Q2 2026.
  • Triumph Capital Management sold 2 Idexx Laboratories shares in Q2 2026, an estimated $1.12K.
  • Idexx Laboratories made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1168 holding.
  • Triumph Capital Management first reported a position in Idexx Laboratories in Q4 2025 and has held it in 3 quarters since.
  • Triumph Capital Management's Idexx Laboratories position peaked at $11.2K in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.